A Phase II Clinical Trial to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) Combined With Nucleoside (Acid) Analogues in Chronic Hepatitis B Patients

A multi-center, randomized, open-label, group controlled study to evaluate the safety and efficacy of T101 combined with nucleoside (acid) analogues in chronic hepatitis B patients.

开始日期2019-12-10

申办/合作机构

天士力医药集团股份有限公司

CTR20192316 / Active, not recruiting临床2期

T101联合核苷（酸）类似物治疗慢性乙型肝炎患者的安全性和有效性的II期临床试验

T101联合核苷（酸）类似物治疗慢性乙型肝炎患者的安全性、有效性及免疫原性，探索最佳的给药方案，为III期方案的设计提供依据

开始日期2019-11-27

申办/合作机构

天士力创世杰（天津）生物制药有限公司

CTR20171453 / Completed临床1期

评价T101在慢性乙肝患者中随机、双盲、安慰剂对照的多剂量、单次、多次给药的耐受性、初步药效学I期临床试验

主要目的：探索T101在慢性乙型肝炎患者中多剂量、单次、多次给药的耐受性。次要目的：评价T101在慢性乙型肝炎患者中的抗病毒活性（HBsAg水平、HBeAg水平的变化）；评价T101对细胞和体液免疫应答的影响。

开始日期2018-01-08

申办/合作机构

天士力创世杰（天津）生物制药有限公司

100 项与治疗用乙型肝炎腺病毒(Transgene) 相关的临床结果

登录后查看更多信息

100 项与治疗用乙型肝炎腺病毒(Transgene) 相关的转化医学

登录后查看更多信息

100 项与治疗用乙型肝炎腺病毒(Transgene) 相关的专利（医药）

登录后查看更多信息

项与治疗用乙型肝炎腺病毒(Transgene) 相关的文献（医药）

2018-12-01·Virology Journal3区 · 医学

Correction to: Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates

3区 · 医学

ArticleOA

作者: Zhao, Shuli ; Wang, Jing ; Zhang, Xuefeng ; Lu, Jing ; Li, Rongrong

Ad-HBV is a product (T101) aiming to treat chronic HBV firstly developed by Transgene S.A., France then by Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd., Tianjin, China in China.

2018-09-01·Journal of Cellular Physiology2区 · 生物学

Transglutaminase activity regulates differentiation, migration and fusion of osteoclasts via affecting actin dynamics

2区 · 生物学

Article

作者: Sun, Huifang ; Kaartinen, Mari T.

Osteoclasts, bone resorbing cells, derive from monocyte/macrophage cell lineage. Increased osteoclast activity is responsible for bone destruction in diseases such as osteoporosis, periodontitis and rheumatoid arthritis. Transglutaminases (TGs), protein crosslinking enzymes, were recently found involved in osteoclastogenesis in vivo, however their mechanisms of action have remained unknown. In this study, we have investigated the role of TG activity in osteoclastogenesis in vitro using four TG inhibitors, NC9, Z006, T101, and monodansyl cadaverine. Our results showed that all TG inhibitors were capable of blocking the entire osteoclastogenesis process. The most potent of the inhibitors, NC9 when added to cultures at different phases of osteoclastogenesis, inhibited differentiation, migration, and fusion of pre‐osteoclasts as well as resorption activity of mature osteoclasts. Further investigation into the mechanisms revealed that NC9 increased RhoA levels and blocked podosome belt formation suggesting that TG activity regulates actin dynamics in pre‐osteoclasts. The inhibitory effect of NC9 on osteoclastogenesis as well as podosome belt formation was completely reversed with a Rho‐family inhibitor Exoenzyme C3. Microtubule architecture, acetylation, and detyrosination of α‐tubulin were not affected. Finally, we demonstrated that macrophages and osteoclasts expressed mRNA of three TGs:TG1, TG2, and Factor XIII‐A which were all differentially regulated in these cells during differentiation. Immunofluoresence microscopic analysis showed that all three enzymes co‐localized to podosomes in osteoclasts. Taken together, our data suggests that TG activity regulates differentiation, migration and fusion of osteoclasts via affecting actin dynamics and that this may involve contribution from all three TG enzymes.

2018-07-04·Nutrition and Cancer4区 · 医学

Transglutaminase 2 Mediates the Cytotoxicity of Resveratrol in a Human Cholangiocarcinoma and Gallbladder Cancer Cell Lines

4区 · 医学

Article

作者: Scricciolo, Alice ; Braidotti, Paola ; Tacchini, Lorenza ; Vaira, Valentina ; Doneda, Luisa ; Tosi, Delfina ; Elli, Luca ; Roncoroni, Leda ; Lombardo, Vincenza ; Branchi, Federica

Resveratrol is a polyphenolic compound extracted from plants and is also a constituent of red wine. Our aim was to evaluate if the cytotoxic effect of resveratrol (RES) on cholangiocarcinoma (CC) and gallbladder cancer (GBC) cell lines could be abolished by TG2 inhibition. Human CC and GBC cell lines (SK-ChA-1 and MZ-ChA-1), grown in a three-dimensional cell culture system (MCTS, multicellular tumor spheroids), were treated for 72 h with RES (32, 64 µM) alone or combined with different TG2 inhibitors (Cystamine, B003, T101). We investigated: cells viability; cell morphology with light microscopy (LM) and transmission electron microscopy (TEM); immunoreactivity with immunohistochemistry; Q-Banding karyotype analysis; TG2 activity; Western blotting. RES treatment induced a significant inhibition of cell growth, ranging from 24% to 76% in both cell lines. The inhibitors successfully reduced TG2 activity without any variation of protein quantity as demonstrated by immunohistochemistry and Western blot. TG2 inhibition resulted in cell growth normalization. In addition, morphologic analysis by light and transmission electron microscopy confirmed the cytotoxic effect of RES and its reduction consequent to TG2 inhibition. Our data demonstrated a connection between the cytotoxic effect of RES in SK-ChA-1 and MZ-ChA-1 and TG2 activity.

项与治疗用乙型肝炎腺病毒(Transgene) 相关的新闻（医药）

2023-05-15

·信狐药迅

亿一生物长效升白新药艾贝格司亭α获批上市，丽珠艾普拉唑获批新适应症 | 新获批（5.8-5.14）

每周药品注册受理数据，分门别类呈现，一目了然。（5.8-5.14）新药上市申请药品名称企业名称分类受理号艾贝格司亭α注射液亿一生物制药(北京)有限公司1CXSS2200018白桦花粉点刺液浙江我武生物科技股份有限公司1CXSS2101078贝伐珠单抗注射液信达生物制药(苏州)有限公司2.2CXSS2101086黄花蒿花粉点刺液浙江我武生物科技股份有限公司1CXSS2101079葎草花粉点刺液浙江我武生物科技股份有限公司1CXSS2200004信迪利单抗注射液信达生物制药(苏州)有限公司2.2CXSS2101085泽布替尼胶囊百济神州(苏州)生物科技有限公司2.4CXHS2200007注射用艾普拉唑钠丽珠集团丽珠制药厂2.4CXHS2200040注射用醋酸曲普瑞林微球丽珠医药集团股份有限公司2.2CXHS2101039新药临床申请药品名称企业名称分类受理号9MW3911注射液南京诺艾新生物技术有限公司1CXSL2300168B901注射液明济生物制药(北京)有限公司1CXSL2300173BSI-060T注射液博奥信生物技术(南京)有限公司1CXSL2300171BTP0717江苏诺和必拓新药研发有限公司2.2;2.4CXHL2300258GR2002注射液重庆智翔金泰生物制药股份有限公司1CXSL23001261CXSL2300127HECB1800301吸入喷雾剂广东东阳光药业有限公司2.2CXHL23002592.2CXHL23002602.2CXHL2300261HRYZ-T101注射液恒瑞源正(上海)生物科技有限公司1CXSL2300144PB-722注射液派格生物医药(苏州)股份有限公司1CXHL2300257PG-011凝胶北京普祺医药科技股份有限公司1CXHL2300226SHR-1654注射液广东恒瑞医药有限公司1CXSL2300158SHR-1905注射液1CXSL2300139SHR7280干混悬剂江苏恒瑞医药股份有限公司1CXHL2300229奥布替尼片北京诺诚健华医药科技有限公司2.4CXHL2300262结核菌素纯蛋白衍生物成都可恩生物科技有限公司2.4CXSL2300130聚乙二醇化重组门冬酰胺酶注射液重庆派金生物科技有限公司1CXSL2300162林普利塞片上海璎黎药业有限公司2.4CXHL2300270氢溴酸氘瑞米德韦干混悬剂苏州旺山旺水生物医药有限公司2.4CXHL23002272.4CXHL2300228人脐带间充质干细胞注射液北京贝来生物科技有限公司1CXSL2300129四价流感病毒裂解疫苗(MDCK细胞)北京生物制品研究所有限责任公司2.2CXSL23001482.2CXSL2300149治疗用卡介苗安徽智飞龙科马生物制药有限公司3.4CXSL2300133重组人源化抗HER2双特异性抗体注射液上海津曼特生物科技有限公司1CXSL2300166注射用SHR-2001广东恒瑞医药有限公司1CXSL2300163注射用阿立哌唑缓释微球辉粒药业(苏州)有限公司2.2CXHL2300266注射用多西他赛(白蛋白结合型)石药集团中奇制药技术(石家庄)有限公司2.4CXHL2300265注射用人源抗IL-17A单克隆抗体冻干粉针山东方坦思生物制药有限公司1CXSL2300140仿制药申请药品名称企业名称分类受理号阿法骨化醇片南京海融制药有限公司4CYHS21011194CYHS2101118奥美沙坦酯片江西施美药业股份有限公司4CYHS2102324奥赛利定富马酸盐注射液江苏恩华药业股份有限公司3CYHS22005163CYHS22002223CYHS22002233CYHS2200224玻璃酸钠滴眼液北京诺思兰德生物技术股份有限公司4CYHS2101660草酸艾司西酞普兰口服溶液浙江国镜药业有限公司3CYHS21015533CYHS2101554醋酸去氨加压素口服溶液杭州和泽坤元药业有限公司3CYHS2200141达比加群酯胶囊浙江华海药业股份有限公司4CYHS21013744CYHS2101373地高辛注射液成都倍特药业股份有限公司3CYHS2200679噁拉戈利片浙江华海药业股份有限公司3CYHL23000213CYHL2300022恩格列净片天地恒一制药股份有限公司4CYHS2200114氟尿嘧啶注射液四川汇宇制药股份有限公司3CYHS21020753CYHS2102074格隆溴铵吸入粉雾剂长风药业股份有限公司4CYHL2300031枸橼酸西地那非片广州祺楠药业科技有限责任公司4CYHS2000924磷酸奥司他韦干混悬剂杨凌科森生物制药有限责任公司3CYHS2200858硫酸沙丁胺醇吸入溶液济南景笙科技有限公司3CYHS21015523CYHS2101551镥[177Lu]氧奥曲肽注射液原子高科股份有限公司3CYHL2300032门冬氨酸鸟氨酸注射液海口市制药厂有限公司6CYHS1301351米力农注射液四川汇宇制药股份有限公司3CYHS21017023CYHS2101701羟乙基淀粉130/0.4氯化钠注射液无锡台裕制药有限公司6CYHS13005916CYHS1300590曲伏前列素滴眼液沈阳兴齐眼药股份有限公司4CYHS2000449替格瑞洛分散片四川海汇药业有限公司4CYHS2101378戊酸二氟可龙乳膏天津金耀药业有限公司3CYHS2000945缬沙坦片浙江诺得药业有限公司4CYHS22001174CYHS2200116盐酸奥洛他定滴眼液山东威智百科药业有限公司4CYHS2101940盐酸多巴胺注射液合肥亿帆生物制药有限公司3CYHS2200063叶酸片北京斯利安药业有限公司3CYHS22013243CYHS2200112注射用尿促性素上海天伟生物制药有限公司6CYHS1101451注射用盐酸吉西他滨南京臣功制药股份有限公司6CYHS1100927左氧氟沙星滴眼液成都普什制药有限公司4CYHS2101922进口申请药品名称企业名称分类受理号IBD98-M缓释胶囊Holy Stone Healthcare Co. Ltd.2.3JXHL2300028Selumetinib胶囊ASTRAZENECA UK LIMITED5.1JXHS22000535.1JXHS2200054Upadacitinib口服溶液AbbVie Inc.2.2JXHL2300042卡前列素氨丁三醇注射液Dr. Reddys Laboratories Limited5.2JYHS2100039培哚普利吲达帕胺氨氯地平片Les Laboratoires Servier5.1JXHS22000265.1JXHS22000275.1JXHS2200028碳酸司维拉姆片印度瑞迪博士实验室有限公司5.2JXHS1900097盐酸依特卡肽注射液Amgen Europe B.V.5.1JXHS21010115.1JXHS21010125.1JXHS2101013注射用阿地白介素CLINIGEN HEALTHCARE LIMITED2.2JXSL2300043注射用福沙匹坦双葡甲胺Aspiro Pharma Limited5.2JYHS2200080中药相关申请药品名称企业名称分类受理号十一方药酒广西中医药大学第一附属医院(广西中医医院)1.1CXZL2300013栀黄贴膏江苏康缘药业股份有限公司1.1CXZL2300014注：灰色字体部分结论为不批准或收到通知件；不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

上市批准疫苗

100 项与治疗用乙型肝炎腺病毒(Transgene) 相关的药物交易

登录后查看更多信息